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1. Introduction: historical concerns about blood pressure determination
The history of hypertension measurements begins in the late 1800s, with the introduction of
the sphygmomanometer, an instrument to measure blood pressure with a noninvasive device.
At that time, some practitioners were still skeptical about the clinical importance of determin‐
ing blood pressure. Others considered it as a valuable tool for diagnosis and began with early
descriptions of the variability of blood pressure among individuals [1].
Additionally, the life insurance industry in the United States played also an important role in
the recognition of an association between blood pressure level and cardiovascular morbidity
and mortality. In the first half of the twentieth century, the use of the sphygmomanometer was
indispensable in life insurance examinations because insurance companies required it for the
applicants. The Actuarial Society of American published a report in 1939 about the relationship
between blood pressure and mortality from cardiovascular and renal diseases. However, the
clinical significance of high blood pressure during this time was not well understood, and
essential hypertension was considered as a compensatory feature of blood pressure to ensure
adequate perfusion of the target organs. This is the explanation why many clinicians were
reluctant to treat high blood pressure because essential hypertension was considered a control
mechanism to assure tissue perfusion, only to be controlled or regulated, even when there was
increasing evidence of the association of cardiovascular disease and mortality with high blood
pressure [2].
The two first clinical trials from the Veterans Administration Cooperative Studies evidenced
the benefits of lowering blood pressure with antihypertensive treatment, published in 1967
and 1971, respectively. The design of both studies served as a prototype for future clinical
trials. Furthermore, on a report in 1979, the Actuarial Society of American concluded that
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mortality ratios rose with an increase in blood pressure in both men and women; they stated
that overweight (35–45% above the average weight) increased mortality considerably in men
with high blood pressure. Coronary disease, cerebral hemorrhage, left ventricular hypertro‐
phy, and renal disease were among the causes of death identified, and mortality of these causes
rose as blood pressure increased [2]. Since then, many studies showed that reduction in high
blood pressure reduces cardiovascular morbidity and mortality for hypertension and served
as evidence for early recommendations for antihypertensive therapy [3].
2. Epidemiologic transition: infectious diseases are replaced by
cardiovascular diseases
During 1940s and 1950s, after World War II, the health priority became the control of infectious
diseases, because they were the major contributors to morbidity and mortality at that time. As
a consequence, the efforts in public health to control and prevent infectious diseases resulted
in the decline in mortality rates and average life expectancy increase. During the twentieth
century, an epidemiologic transition was evident in developed countries, in which infectious
disease pandemics were replaced as a major cause of death by chronic degenerative diseases,
such as cardiovascular diseases [4].
Since mortality rate for cardiovascular disease had been increasing progressively, the National
Health Institute, in USA (now known as the National Heart, Lung, and Blood Institute) decided
to conduct an ambitious project in 1948: the Framingham Heart Study. The researchers of the
project recruited more than 5000 men and women who had not suffered symptoms of
cardiovascular disease or had a cardiovascular event—heart attack or stroke, and analyzed
them over a long period of time [5, 6]. As a prospective longitudinal epidemiologic study, its
objective was to characterize the population subject to cardiovascular disease. The original
cohort was followed up over decades, enrolling a second and a third generation to the original
cohort. Since 1951, several articles were published based on research results of the Framingham
Study, obtained by the careful monitoring of the study population, which led to the identifi‐
cation of the major coronary heart disease risk factors—high blood pressure, high cholesterol
levels, smoking, obesity, diabetes, physical inactivity, closely related to other factors such as
blood triglyceride and HDL cholesterol levels, age, gender, and psychosocial issues.
3. Essential hypertension: definition and etiology
Essential hypertension, also known as primary or idiopathic hypertension, is the presence of
high blood pressure not explainable by secondary causes, representing 95% of all cases of high
blood pressure. Secondary causes of hypertension are aldosteronism, renal disease, pheochro‐
mocytoma, hyperthyroidism, etc. [7].
Essential hypertension is a quantitative characteristic, defined by its strong positive correlation
between blood pressure and risk of cerebral or cardiac, events and kidney disease. The etiology
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of essential hypertension is complex, and it is possible that multiple factors interact and
produce hypertension. Furthermore, it has become notorious that a genetic susceptibility and
the interaction of environmental factors, such as stress, diet, and physical activity play a
relevant role in the pathogenesis of hypertension, as suggested in 1949 by Page in his mosaic
theory to explain the possible mechanisms involved in the etiology of hypertension (Fig‐
ure 1) [8]. The development of essential hypertension is composed of a primary process, in
which vasoconstriction raises blood pressure initially, followed by a secondary amplifying
process, in which the difference in blood pressure rises throughout life. This primary event
can be in the perinatal and early postnatal life, a phenomenon known as ‘intrauterine pro‐
gramming’, important in long‐term effects on the subsequent development of high blood
pressure, with possible onset of hypertension during childhood and adolescence.
In developed countries, there is a probability of 90% of becoming hypertensive during the
lifetime. Risk factors often cluster with other cardiovascular risk factors in individuals with an
unhealthy lifestyle, including the sedentary lifestyle, smoking, stressful life of industrialized
societies and Western diet patterns. Among dietary factors, it has been demonstrated that
excessive salt intake, high alcohol consumption, low intake of potassium and calcium are
related to hypertension. On the other hand, an increased consumption of polyunsaturated fatty
acids of the omega‐3 family has shown to have a hypotensive effect and reduces the cardio‐
vascular risk.
Furthermore, blood pressure is affected by several environmental factors such as ambient
temperature, air pollution, and noise. In addition, the repeated or prolonged exposure to these
factors leads consequently to an increased sympathetic and adrenal activity [9]. Likewise,
stress related situations, such as job strain, emotional distress, and social environment can
cause hypertension through repeated blood pressure elevation and increased secretion of
vasoconstrictive hormones.
Figure 1. Interactions of factors in essential hypertension development, modified from the original Paige's mosaic theo‐
ry of blood pressure regulation [8]. There is a circuitry of several factors interacting in an individual that may lead to
the development of essential hypertension, such as genetic background, diet, physical activity, psychosocial factors,
environmental factors, obesity, insulin resistance, dyslipidemia and stress.
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Recognition of a genetic basis in hypertension is deduced from epidemiological and family
studies, such as the Framingham Study [10]. Genetic alterations and polymorphisms in
inherited ‘essential’ hypertension have also been identified. As a result, the individual
response to the environmental factors mentioned above is variable, because the effect of an
allelic variation of any gene depends on the environment in which the gene is expressed. In
summary, it becomes clear that various factors contribute to blood pressure elevation in
essential hypertension in susceptible individuals.
4. Twenty‐first century challenges: genetic strategies and personalized
medicine
Hypertension is a major contributor to cardiovascular disease, a leading cause of death in many
countries. For this reason, there exists a commitment of many health organizations worldwide,
to continue initiatives of research in hypertension. In the last twenty years, the use of experi‐
mental animal models for hypertension‐related research has provided information in various
aspects of the disease, which includes etiology, pathophysiology, complications, and treat‐
ment. In addition, comparative mapping techniques allow comparison of the syntenic genomic
regions between rodents and the human genome. Recently, the identification of the role of
cardiovascular genetic determinants of hypertension through linkage analyses and genome‐
wide scan studies permits a better understanding of the complex genetic architecture of the
disease [11]. Numerous genes have been identified, including the genes from the renin‐
angiotensin‐aldosterone system, the epithelial sodium channel, the adrenergic receptor,
endogenous adducin, etc.
Furthermore, pharmacogenetics association studies in hypertensive patients are a useful tool
helping to individualize therapy, by predicting patient response to a treatment, chosen to
provide greatest clinical efficacy with the lowest risk of adverse effects.
5. Conclusion
During the twenty‐first century, it has been a challenge to find the genetic etiology of human
essential hypertension. Many studies on genetics and pharmacogenomics of hypertension
have served as the basis, facilitating results of the role of candidate genes. However, as high
blood pressure results from a complex interplay of diverse environmental and genetic factors,
the replication of many studies has been problematic. The application of genetic data to the
current therapeutic guidelines must be encouraged because provided evidence from several
studies has not readily been translated into personalized medicine. The heterogeneity and
complexity of the genetic network that in interaction with the environment controls the
physiological mechanisms involved in blood pressure regulation has hampered the clinical
application of animal genetic results to humans [12]. Additional discoveries in hypertension
pharmacogenomics are expected to be obtained from genome‐wide association studies. In
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order to translate the findings of candidate gene studies and genome‐wide association studies
to the clinical practice, more efficient genetic testing, denser mapping techniques, full utiliza‐
tion of animal models and increased collaboration among research groups need to be im‐
proved.
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